GLP-1 Peptides: A Canadian Researcher's Guide to the Incretin Family (2026)

A GLP-1 peptide is a synthetic analog or derivative of glucagon-like peptide-1 — a 30-amino-acid incretin hormone — engineered to resist rapid enzymatic degradation and sustain activity at the GLP-1 receptor in research models. The incretin-agonist family now extends well beyond the first-generation single agonists: it encompasses dual GIP/GLP-1 co-agonists, triple GIP/GLP-1/glucagon agonists, amylin analogs studied in combination protocols, and a growing slate of next-generation compounds in published phase 2 and phase 3 trials.

This guide is written for Canadian researchers and research-adjacent buyers who need a compliance-first overview of the full GLP-1 peptide family, the published mechanism literature, and the methodological considerations that apply when handling these compounds in a laboratory setting. Every product family below links to its PinPoint Peptides product page; every research claim is cited to the primary literature.

Key Takeaways

GLP-1 is a 30-amino-acid incretin hormone that signals through a class B G protein-coupled receptor via the Gs-cAMP-PKA pathway (Drucker, 2018).

The research-peptide family spans single agonists (semaglutide), dual GIP/GLP-1 agonists (tirzepatide), triple GIP/GLP-1/glucagon agonists (retatrutide), amylin analogs (cagrilintide), and next-generation GLP-1/glucagon compounds (mazdutide, survodutide).

Published trials by Wilding et al. (2021), Jastreboff et al. (2022, 2023), and Rosenstock et al. (2021) established the phase 3 evidence base across these classes.

Research-use-only GLP-1 peptides are supplied in lyophilized form and reconstituted with bacteriostatic water for laboratory applications only.

The Canadian research-peptide market operates in a regulatory gray area: research-grade material is not a Health Canada-approved therapeutic and must be sourced with third-party Certificate of Analysis (COA) documentation.

What Are GLP-1 Peptides?

GLP-1 (glucagon-like peptide-1) is an incretin hormone cleaved from the proglucagon gene and secreted primarily by intestinal L-cells in response to nutrient ingestion. The biologically active forms are GLP-1(7-36) amide and GLP-1(7-37), both 30-amino-acid peptides (Drucker, 2018). Native GLP-1 has a plasma half-life of approximately two minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4), which limits its direct utility as a research reagent. The pharmacological-research peptides in this class are engineered analogs that resist DPP-4 degradation and extend receptor engagement.

The GLP-1 receptor (GLP-1R) is a class B G protein-coupled receptor expressed in pancreatic beta cells, intestinal epithelium, hypothalamic nuclei, brainstem regions, and cardiac tissue. Receptor activation signals through the Gs-cAMP-PKA pathway and, at higher occupancy, engages beta-arrestin-mediated pathways. In pancreatic research models, activation promotes glucose-dependent insulin secretion; in central nervous system models, activation in the arcuate nucleus and nucleus of the solitary tract has been studied in the context of satiety and food-intake regulation (Drucker, 2018).

The "incretin effect" — the observation that oral glucose produces a greater insulin response than matched intravenous glucose — is the conceptual basis for the entire research category. The effect is primarily attributed to two hormones: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). Next-generation research peptides target both receptors (tirzepatide) or combine them with glucagon-receptor agonism (retatrutide) to probe questions that single-agonist compounds cannot answer in isolation.

In research terminology, the phrase "GLP-1 peptide" is used in two related but distinct ways. In the strictest sense, it refers to native GLP-1 and its direct analogs — peptides that bind the GLP-1 receptor specifically. In the broader research-catalog sense — the sense used on vendor product pages, in Canadian laboratory procurement lists, and throughout this guide — the phrase covers the wider incretin-family taxonomy: single GLP-1 agonists, dual GIP/GLP-1 agonists, triple GIP/GLP-1/glucagon agonists, and the amylin-analog compounds studied alongside them in published combination trials. This guide uses the broader sense because it reflects how the research-peptide category is actually structured for Canadian procurement.

The GLP-1 Agonist Family: A Research-Category Taxonomy

The PinPoint Peptides GLP-1 lineup covers the complete incretin-agonist taxonomy from first-generation single agonists to next-generation multi-receptor compounds. Browse the full GLP-1 peptide catalog for current stock, or use the breakdown below to understand how each research compound fits the family tree.

First-Generation Single GLP-1 Agonists

Semaglutide is the canonical long-acting GLP-1 receptor agonist. Engineered with two amino-acid substitutions (Aib8 and Arg34) and a C-18 fatty di-acid linker that binds serum albumin, semaglutide achieves a plasma half-life of roughly seven days in published pharmacokinetic studies (Knudsen and Lau, 2019). The STEP (Semaglutide Treatment Effect in People with Obesity) and SELECT trial programs established the phase 3 evidence base for metabolic and cardiovascular endpoints, respectively (Wilding et al., 2021; Lincoff et al., 2023). For the full trial-data breakdown, see the semaglutide GLP-1 receptor research summary. Research-grade material is available on the semaglutide product page across 2mg, 5mg, 10mg, 15mg, 20mg, and 30mg vial formats.

Dual GIP/GLP-1 Co-Agonists

Tirzepatide is the first clinically validated dual agonist, engaging both the GIP and GLP-1 receptors with a single 39-amino-acid peptide (Coskun et al., 2018). The receptor-binding profile differs from native incretins: tirzepatide is biased toward GIP-receptor engagement and shows altered beta-arrestin recruitment at the GLP-1 receptor relative to native GLP-1. The SURPASS program (type 2 diabetes) and SURMOUNT program (body-composition research) have published head-to-head and placebo-controlled data across multiple phase 3 trials (Frías et al., 2021; Jastreboff et al., 2022). Research-grade tirzepatide is stocked in 5mg through 60mg vial formats on the tirzepatide product page.

Triple GIP/GLP-1/Glucagon Agonists

Retatrutide is the furthest-developed triple agonist, engaging the GIP, GLP-1, and glucagon receptors with balanced activity at each (Coskun et al., 2022). Glucagon-receptor co-agonism is the mechanistic novelty: glucagon activates hepatic lipolysis and increases basal energy expenditure in published metabolic models, a pathway that single- and dual-agonist compounds do not engage. The phase 2 trial published by Jastreboff et al. (2023) in the New England Journal of Medicine documented the largest observed body-composition changes yet reported for an incretin-class research compound at 48 weeks. For a deeper research summary, see the retatrutide research overview. Research-grade vials (5mg through 60mg) are available on the retatrutide product page.

Amylin Analogs and Combination Research

Cagrilintide is a long-acting analog of amylin — a 37-amino-acid pancreatic hormone co-secreted with insulin that binds the amylin receptor family (AMY1R, AMY2R, AMY3R). Amylin-receptor activation has been studied as an independent satiety pathway that complements, rather than duplicates, incretin signaling. The most-studied combination is CagriSema (cagrilintide + semaglutide), evaluated in phase 1b and phase 2 trials by Enebo et al. (2021) and subsequent follow-on work published in The Lancet. PinPoint stocks cagrilintide in 5mg and 10mg vial formats on the cagrilintide product page.

Next-Generation Dual and Adjacent Compounds

Mazdutide (IBI362) is a GLP-1/glucagon dual agonist developed jointly by Innovent Biologics and Eli Lilly, with phase 2 data published in The Lancet by Ji et al. (2023). Survodutide (BI 456906) is a GLP-1/glucagon dual agonist from Boehringer Ingelheim and Zealand Pharma, with phase 2 hepatic-research data published by Sanyal et al. (2024). 5-Amino-1MQ is a nicotinamide N-methyltransferase (NNMT) inhibitor — not a GLP-1 agonist, but studied in the same adipocyte-metabolism research niche (Neelakantan et al., 2018). The broader category hub lists current inventory for all of these.

Legacy Lipolysis Research Peptide

AOD-9604 is a modified fragment of the C-terminus of human growth hormone (amino acids 177-191) studied across two decades for its activity in lipolysis assays (Heffernan et al., 2001). It pre-dates the incretin-agonist category but remains relevant as an adjacent metabolic-research compound. See the existing AOD-9604 lipid metabolism research summary for the published literature.

Research Mechanisms: How GLP-1 Receptor Activation Has Been Studied

The GLP-1 receptor belongs to the secretin-like (class B) subfamily of GPCRs, distinguished by a long extracellular N-terminal domain that forms the primary peptide-binding interface. Structural studies using cryo-electron microscopy have resolved the active-state GLP-1R in complex with semaglutide and with tirzepatide, clarifying how single- and dual-agonist peptides engage the receptor at atomic resolution (Zhang et al., 2017; Sun et al., 2020).

Canonical signaling proceeds through Gs coupling: GLP-1R activation stimulates adenylate cyclase, elevates intracellular cAMP, and activates protein kinase A (PKA) and the cAMP-responsive guanine nucleotide exchange factor Epac2. In pancreatic beta-cell research models, this cascade amplifies glucose-stimulated insulin secretion by closing ATP-sensitive potassium channels and promoting insulin-granule exocytosis. Importantly, the effect is glucose-dependent — the compound does not drive insulin release under low-glucose conditions, a pharmacological property documented across the incretin-agonist class (Drucker, 2018).

In central nervous system research, GLP-1R is expressed in the arcuate nucleus of the hypothalamus, the area postrema, the nucleus of the solitary tract, and vagal afferents. Preclinical food-intake studies using receptor-knockout rodent models have dissected which population contributes to observed satiety effects. The GIP receptor adds a complementary mechanism: GIP-receptor signaling in adipose tissue has been studied in the context of nutrient storage and insulin sensitization, and tirzepatide's dual agonism is hypothesized to exploit this pathway (Coskun et al., 2018). Glucagon-receptor agonism in retatrutide adds a third axis: hepatic lipolysis, increased resting energy expenditure, and altered amino-acid metabolism (Coskun et al., 2022).

Biased agonism — the observation that different ligands engage different downstream pathways at the same receptor — is an active research question across the class. Semaglutide and tirzepatide show distinct beta-arrestin recruitment and receptor-internalization profiles in cell-based assays, and these differences are hypothesized to contribute to the distinct trial outcomes observed between the two compounds (Willard et al., 2020).

Pharmacokinetics Across the Family

A shared engineering feature across the modern incretin-agonist research peptides is extended plasma half-life. Native GLP-1 is degraded by dipeptidyl peptidase-4 within minutes; the research analogs use a range of strategies to resist this cleavage and extend circulating exposure. Semaglutide substitutes alanine-8 with aminoisobutyric acid (Aib) — a non-native residue that DPP-4 cannot cleave — and adds a C-18 fatty di-acid moiety at lysine-26 that binds serum albumin, producing a ~7-day plasma half-life (Knudsen and Lau, 2019). Tirzepatide uses a similar fatty-acid-linker approach on a GIP-based sequence, yielding a ~5-day half-life. Retatrutide extends the approach with a C-20 fatty diacid moiety, producing a ~6-day half-life across its phase 1 dose-ranging cohorts (Coskun et al., 2022). The shared consequence for research design is that once-weekly administration protocols are consistent across the category.

Receptor Selectivity and Structural Biology

Cryo-electron microscopy has resolved the active-state GLP-1 receptor in complex with a G protein and with several of its clinically validated ligands, including semaglutide (Zhang et al., 2017) and tirzepatide (Sun et al., 2020). These structures show that the peptide ligand engages the receptor's extracellular N-terminal domain and transmembrane bundle through a two-step binding mechanism. Subtle differences in how each ligand orients in the binding pocket map onto the distinct biased-agonism signatures observed in cell-based assays — and, by extension, onto the trial-outcome differences observed across the category. Structural biology is increasingly being used by research groups to predict how novel multi-agonist designs will behave before the expense of an in vivo study.

Methodological Considerations for GLP-1 Peptide Research

GLP-1 research peptides are supplied as lyophilized powders under nitrogen or argon atmosphere, typically in sealed glass vials. The methodology discussion below applies to all incretin-family compounds PinPoint stocks; per-vial worked examples for each format are in the peptide reconstitution guide and the reconstitution calculator.

Reconstitution

Reconstitution is performed with bacteriostatic water — water containing 0.9% benzyl alcohol as a preservative — which is the standard solvent for injectable-format research peptides in a laboratory context. The lyophilized cake is rehydrated by introducing the solvent slowly down the inner vial wall, allowing the peptide to dissolve without agitation. Vortexing is avoided; gentle swirling is the documented norm. The target research concentration is chosen to match the experimental protocol: a 5mg vial reconstituted in 1mL yields a 5mg/mL stock solution for research dilution.

Storage and Stability

Lyophilized GLP-1 peptides stored at -20°C in the unopened vial remain stable for the duration of the documented shelf life (typically 24 months from manufacture, confirmed on the batch COA). Post-reconstitution, the research norm is refrigerated storage at 2-8°C with a documented stability window of 28 days for most incretin-class compounds. See the peptide storage guide for compound-specific temperature and shelf-life data. Repeated freeze-thaw cycles are avoided; if long-term post-reconstitution storage is required, aliquoting at preparation time is the standard protocol.

Identity and Purity Verification

Every research-grade GLP-1 peptide batch PinPoint ships includes a third-party Certificate of Analysis documenting HPLC purity (typically 98%+), mass-spectrometry identity confirmation, and endotoxin levels. For peptides intended for in vivo research, the endotoxin specification matters: the typical research-grade ceiling is under 10 EU/mg. For a full walkthrough of how to read these documents, see how to read a peptide Certificate of Analysis. Peptides without a current third-party COA should not be used in research protocols where batch traceability is required.

The Canadian Research Context

Canadian researchers sourcing GLP-1 peptides operate in a distinct regulatory and logistical environment. Health Canada regulates therapeutic drugs under the Food and Drugs Act; research-use-only peptides are not Health Canada-approved therapeutics and are supplied strictly for laboratory research applications, not human use. The regulatory posture following the August 2025 enforcement actions against certain Canadian peptide vendors has tightened the category's compliance expectations — see are peptides legal in Canada for the current regulatory analysis.

Domestic sourcing offers practical advantages for Canadian research labs: no US-Canada customs processing (which commonly adds 1-3 weeks for peptide shipments), CAD pricing without FX exposure, and Canada Post tracking from a Canadian origin. PinPoint ships insured and tracked from a Canadian warehouse, with Interac e-Transfer as the default payment method for research-account customers.

Canadian COA expectations for GLP-1 peptides follow the same international standards used by university and private-sector research labs: HPLC purity of 98% or higher, mass-spectrometry identity confirmation matching the expected monoisotopic mass, and endotoxin documentation. For a full framework for evaluating peptide vendors in Canada, see the complete Canadian peptide buyer's guide and peptide purity testing — why 98%+ matters.

Comparing Compounds in Published Research

Head-to-head data between GLP-1 family peptides exists only in a narrow set of published trials. Direct comparisons have been published for:

Semaglutide vs. tirzepatide: SURPASS-2 (Frías et al., 2021) compared tirzepatide (5mg, 10mg, 15mg weekly) with semaglutide 1mg weekly in participants with type 2 diabetes over 40 weeks, reporting HbA1c and body-weight endpoints across all arms.
Retatrutide vs. placebo: Jastreboff et al. (2023) phase 2 trial reported 48-week body-composition data across 1mg, 4mg, 8mg, and 12mg weekly arms. No phase 3 head-to-head against tirzepatide has yet been published, though phase 3 trials are underway.
CagriSema vs. semaglutide: Enebo et al. (2021) phase 1b evaluated cagrilintide + semaglutide against semaglutide monotherapy in short-duration endpoints.

The dual- and triple-agonist compounds show larger effect sizes than semaglutide alone in the body-composition endpoints reported in these trials, though comparison across trials with different endpoints and populations is not equivalent to a head-to-head design. The forthcoming retatrutide vs. tirzepatide research comparison works through the pharmacology side-by-side. All observations here describe outcomes in trial participants as reported in the published literature, not therapeutic claims.

Frequently Asked Questions

What is the difference between GLP-1 and a GLP-1 agonist?

GLP-1 is the native 30-amino-acid incretin hormone secreted by intestinal L-cells. A GLP-1 agonist is a synthetic peptide (such as semaglutide) engineered to bind and activate the same receptor while resisting the rapid DPP-4 cleavage that limits native GLP-1's plasma half-life to about two minutes (Drucker, 2018).

What is the GLP-1 agonist mechanism of action?

GLP-1 agonists bind the GLP-1 receptor — a class B G protein-coupled receptor — and activate Gs-cAMP-PKA signaling. In pancreatic research models this amplifies glucose-dependent insulin secretion; in central nervous system models, receptor activation in hypothalamic and brainstem regions has been studied in the context of satiety signaling. Dual agonists (tirzepatide) add GIP-receptor engagement; triple agonists (retatrutide) further add glucagon-receptor engagement (Coskun et al., 2018; Coskun et al., 2022).

How many GLP-1 drugs are there?

The incretin-agonist research-peptide family currently includes approximately a dozen compounds with published phase 1 or later data, across four mechanistic classes: single GLP-1 agonists (semaglutide, liraglutide, dulaglutide, exenatide), dual GIP/GLP-1 agonists (tirzepatide), triple GIP/GLP-1/glucagon agonists (retatrutide), and GLP-1/glucagon dual agonists (mazdutide, survodutide, efinopegdutide). Adjacent research peptides include the amylin analog cagrilintide.

Are GLP-1 peptides legal in Canada for research?

Research-grade GLP-1 peptides are sold for laboratory research use only in Canada. They are not Health Canada-approved therapeutic products and are not for human consumption. Canadian labs working with these compounds must document their research-use context; vendors must ship with a research-use disclaimer and a batch COA. See the current regulatory analysis of peptides in Canada for detail.

What is the highest-purity research-grade GLP-1 peptide?

PinPoint's research-grade GLP-1 peptides ship with HPLC purity of 98% or higher, confirmed by third-party analytical lab testing on every batch. The COA documents the exact purity percentage, mass-spec identity confirmation, and endotoxin levels; see how to read a peptide COA for the full interpretation framework.

How are GLP-1 peptides reconstituted for research use?

Lyophilized GLP-1 peptides are reconstituted with bacteriostatic water introduced slowly down the inner vial wall, allowing the peptide to dissolve without agitation. The target research concentration depends on the experimental protocol. The reconstitution calculator computes the solvent volume required for any target concentration across the vial sizes PinPoint ships.

Conclusion

The GLP-1 peptide family has expanded dramatically in the past five years — from a single-agonist category dominated by semaglutide into a multi-receptor research landscape with dual agonists (tirzepatide), triple agonists (retatrutide), amylin combinations (cagrilintide), and next-generation GLP-1/glucagon compounds (mazdutide, survodutide). For Canadian researchers building a sourcing pipeline, the priorities are consistent regardless of which specific compound is under study: third-party COA documentation, appropriate reconstitution and storage methodology, and a compliance-first research-use-only register.

These compounds are research chemicals, not therapeutics. Every observation summarized here derives from the published literature and applies to laboratory or trial contexts, not individual use. Browse the full GLP-1 peptide catalog for Canadian-domestic supply with COA documentation on every batch, or read the deeper retatrutide research summary for a worked example of how PinPoint documents a next-generation research compound.

References

Drucker, D.J. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 27.4 (2018): 740-756.
Knudsen, L.B., and Lau, J. "The discovery and development of liraglutide and semaglutide." Frontiers in Endocrinology 10 (2019): 155.
Wilding, J.P.H., et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine 384.11 (2021): 989-1002.
Lincoff, A.M., et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." New England Journal of Medicine 389.24 (2023): 2221-2232.
Coskun, T., et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept." Molecular Metabolism 18 (2018): 3-14.
Frías, J.P., et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." New England Journal of Medicine 385.6 (2021): 503-515.
Jastreboff, A.M., et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine 387.3 (2022): 205-216.
Coskun, T., et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept." Cell Metabolism 34.9 (2022): 1234-1247.
Jastreboff, A.M., et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." New England Journal of Medicine 389.6 (2023): 514-526.
Rosenstock, J., et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial." The Lancet 402.10401 (2023): 529-544.
Enebo, L.B., et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial." The Lancet 397.10286 (2021): 1736-1748.
Ji, L., et al. "Mazdutide in Chinese adults with obesity or overweight: a randomised, double-blind, placebo-controlled, phase 2 trial." The Lancet Diabetes & Endocrinology 11.9 (2023): 672-682.
Sanyal, A.J., et al. "A phase 2 randomized trial of survodutide in MASH and fibrosis." New England Journal of Medicine 391.4 (2024): 311-319.
Zhang, Y., et al. "Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein." Nature 546.7657 (2017): 248-253.
Sun, W., et al. "Structures of human GLP-1 receptor-Gs complex reveal molecular basis for peptide agonism." Nature Communications 11.1 (2020): 4121.
Willard, F.S., et al. "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight 5.17 (2020): e140532.
Heffernan, M.A., et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice." Endocrinology 142.12 (2001): 5182-5189.
Neelakantan, H., et al. "Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle." Biochemical Pharmacology 163 (2019): 481-492.

Related Resources

For research purposes only. Not for human consumption. This product is not a drug, food, or cosmetic and is not intended to diagnose, treat, cure, or prevent any disease. Must be 18+ to purchase. PinPoint Peptides is not a pharmacy and does not provide medical advice.